The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Chemoresistance in Pancreatic Cancer
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC), generally known as pancreatic cancer (PC), ranks the fourth leading cause of cancer-related deaths in the western world. While the incidence of pancreatic cancer is displaying a rising tendency every year, the mortality rate has not decreased significantly because of late diagnosis, early metastasis, and limited reaction to chemotherapy or radiotherapy. Adjuvant chemotherapy after surgical resection is typically the preferred option to treat early pancreatic cancer. Although 5-fluorouracil/leucovorin with irinotecan and oxaliplatin (FOLFIRINOX) and gemcitabine/nab-paclitaxel can profoundly improve the prognosis of advanced pancreatic cancer, the development of chemoresistance still leads to poor clinical outcomes. Chemoresistance is multifactorial as a result of the interaction among pancreatic cancer cells, cancer stem cells, and the tumor microenvironment. Nevertheless, more pancreatic cancer patients will benefit from precision treatment and targeted drugs. Therefore, we outline new perspectives for enhancing the efficacy of gemcitabine after reviewing the related factors of gemcitabine metabolism, mechanism of action, and chemoresistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Galván, J. A., Zlobec, I., Wartenberg, M., Lugli, A., Gloor, B., Perren, A. A., & Karamitopoulou, E. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.177 · Cited by 155
RetractedLi, C., Zhao, Z., Zhou, Z., & Liu, R. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3178-4 · Cited by 86
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationFOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Genome-scale CRISPR-Cas9 Knockout and Transcriptional Activation Screening
Joung, J., Konermann, S., Gootenberg, J. S., Abudayyeh, O. O., Platt, R. J., Brigham, M. D., Sanjana, N. E., & Zhang, F. (2017) · Nature Protocols · doi:10.1038/nprot.2017.016 · Cited by 1,243
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer
Watkins, D. N., Berman, D. M., Burkholder, S. G., Wang, B., Beachy, P. A., & Baylin, S. B. (2003) · Nature · doi:10.1038/nature01493 · Cited by 1,082
Hedgehog signalling in prostate regeneration, neoplasia and metastasis
Karhadkar, S. S., Steven Bova, G., Abdallah, N., Dhara, S., Gardner, D., Maitra, A., Isaacs, J. T., Berman, D. M., & Beachy, P. A. (2004) · Nature · doi:10.1038/nature02962 · Cited by 950
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1991) · PubMed · Cited by 876
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Arumugam, T., Ramachandran, V., Fournier, K. F., Wang, H., Marquis, L., Abbruzzese, J. L., Gallick, G. E., Logsdon, C. D., McConkey, D. J., & Choi, W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2819 · Cited by 863
Cellular pharmacology of gemcitabine
Mini, E., Nobili, S., Caciagli, B., Landini, I., & Mazzei, T. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj941 · Cited by 842
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Plunkett, W. K., Huang, P., Xu, Y.-Z., Heinemann, V., Grunewald, R., & Gandhi, V. V. (1995) · PubMed · Cited by 753
Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., Scheithauer, W., Siena, S., Tabernero, J., Teixeira, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju413 · Cited by 658
Mechanisms of Hedgehog pathway activation in cancer and implications for therapy
Scales, S. J., & de Sauvage, F. J. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.03.007 · Cited by 650
Mackey, J. R., Mani, R. S., Selner, M., Mowles, D., YOUNG, J., Belt, J. A., Crawford, C. R., & Cass, C. E. (1998) · PubMed · Cited by 599
Shukla, S. K., Purohit, V., Mehla, K., Gunda, V., Chaika, N. V., Vernucci, E., King, R. J., Abrego, J., Goode, G. D., Dasgupta, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.004 · Cited by 540
Murphy, J. E., Wo, J. Y., Ryan, D. P., Clark, J. W., Jiang, W., Yeap, B. Y., Drapek, L. C., Ly, L., Baglini, C. V., Blaszkowsky, L. S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0892 · Cited by 522
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Bailey, J. M., Swanson, B. J., Hamada, T., Eggers, J. P., Singh, P. K., Caffery, T., Ouellette, M. M., & Hollingsworth, M. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0291 · Cited by 519
EMT: Mechanisms and therapeutic implications
Singh, M., Yelle, N., Venugopal, C., & Singh, S. K. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.009 · Cited by 475
Maréchal, A., & Zou, L. (2015) · Cell Research · doi:10.1038/cr.2014.147 · Cited by 465
Pietanza, M. C., Waqar, S. N., Krug, L. M., Dowlati, A., Hann, C. L., Chiappori, A., Owonikoko, T. K., Woo, K. M., Cardnell, R. J., Fujimoto, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.7672 · Cited by 399
The role of stromal cancer-associated fibroblasts in pancreatic cancer
von Ahrens, D., Bhagat, T. D., Nagrath, D., Maitra, A., & Verma, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0448-5 · Cited by 389
Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
Bergman, A. M., Pinedo, H. M., & Peters, G. J. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00002-x · Cited by 360
Lok, B. H., Gardner, E. E., Schneeberger, V. E., Ni, A., Desmeules, P., Rekhtman, N., de Stanchina, E., Teicher, B. A., Riaz, N., Powell, S. N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1040 · Cited by 344
Heinemann, V., Xu, Y.-Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1992) · PubMed · Cited by 328
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Murai, J., Feng, Y., Yu, G. K., Ru, Y., Tang, S.-W., Shen, Y., & Pommier, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12266 · Cited by 297
SLFN11 Blocks Stressed Replication Forks Independently of ATR
Murai, J., Tang, S.-W., Leo, E., Baechler, S. A., Redon, C. E., Zhang, H., Al Abo, M., Rajapakse, V. N., Nakamura, E., Jenkins, L. M. M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.01.012 · Cited by 275
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
Ireland, L., Santos, A., Ahmed, M. S., Rainer, C., Nielsen, S. R., Quaranta, V., Weyer-Czernilofsky, U., Engle, D. D., Perez-Mancera, P. A., Coupland, S. E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1201 · Cited by 243
Role of microRNA in anticancer drug resistance
Zheng, T., Wang, J., Chen, X., & Liu, L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24782 · Cited by 233
Goan, Y.-G., Zhou, B., Hu, E., Mi, S., & Yen, Y. (1999) · PubMed · Cited by 227
Early Diagnosis of Pancreatic Cancer: Challenges and New Developments
Kaur, S., Baine, M. J., Jain, M., Sasson, A. R., & Batra, S. K. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.69 · Cited by 220
Weiss, G. J., Blaydorn, L., Beck, J., Bornemann-Kolatzki, K., Urnovitz, H., Schütz, E., & Khemka, V. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0525-1 · Cited by 217
Duluc, C., Moatassim‐Billah, S., Chalabi‐Dchar, M., Perraud, A., Samain, R., Breibach, F., Gayral, M., Cordelier, P., Delisle, M., Bousquet‐Dubouch, M., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404346 · Cited by 214
Nakahira, S., Nakamori, S., Tsujie, M., Takahashi, Y., Okami, J., Yoshioka, S., Yamasaki, M., Marubashi, S., Takemasa, I., Miyamoto, A., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22390 · Cited by 209
Equilibrative nucleoside transporters—A review
Boswell-Casteel, R. C., & Hays, F. A. (2017) · Nucleosides, Nucleotides and Nucleic Acids · doi:10.1080/15257770.2016.1210805 · Cited by 209
Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells
Sari, I. N., Phi, L. T. H., Jun, N., Wijaya, Y. T., Lee, S., & Kwon, H. Y. (2018) · Cells · doi:10.3390/cells7110208 · Cited by 202
Acquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
Zhang, D., Li, L., Jiang, H., Li, Q., Wang-Gillam, A., Yu, J., Head, R., Liu, J., Ruzinova, M. B., & Lim, K.-H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1366 · Cited by 190
Costantino, C. L., Witkiewicz, A. K., Kuwano, Y., Cozzitorto, J. A., Kennedy, E. P., Dasgupta, A., Keen, J. C., Yeo, C. J., Gorospe, M., & Brody, J. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0371 · Cited by 181
Murai, J., Thomas, A., Miettinen, M., & Pommier, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.009 · Cited by 172
Nogales, V., Reinhold, W. C., Varma, S., Martinez-Cardus, A., Moutinho, C., Moran, S., Heyn, H., Sebio, A., Barnadas, A., Pommier, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6413 · Cited by 169
Maresch, R., Mueller, S., Veltkamp, C., Öllinger, R., Friedrich, M., Heid, I., Steiger, K., Weber, J., Engleitner, T., Barenboim, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms10770 · Cited by 166
Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
Dauer, P., Nomura, A., Saluja, A., & Banerjee, S. (2016) · Pancreatology · doi:10.1016/j.pan.2016.12.010 · Cited by 165
Skrypek, N., Duchêne, B., Hebbar, M., Leteurtre, E., SEUNINGEN, I. V., & Jonckheere, N. (2012) · Oncogene · doi:10.1038/onc.2012.179 · Cited by 157
A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study
Kaur, S., Smith, L. M., Patel, A., Menning, M., Watley, D. C., Malik, S. S., Krishn, S. R., Mallya, K. B., Aithal, A., Sasson, A. R., et al. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.482 · Cited by 157
Ślusarczyk, M., Lopez, M. H., Balzarini, J. M., Mason, M. D., Jiang, W. G., Blagden, S. P., Thompson, E., Ghazaly, E. A., & McGuigan, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401853a · Cited by 153
Labori, K. J., Katz, M. H. G., Tzeng, C. W., Bjørnbeth, B. A., Cvancarova, M., Edwin, B., Kure, E. H., Eide, T. J., Dueland, S., Buanes, T. A., et al. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1068445 · Cited by 152
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.
Rauchwerger, D. R., Firby, P., Hedley, D. W., & Moore, M. J. (2000) · PubMed · Cited by 150
Kang, J., Hwang, I., Yoo, C., Kim, K., Jeong, J. H., Chang, H.-M., Lee, S. S., Park, D. H., Song, T. J., Seo, D. W., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0598-5 · Cited by 131
Li, M., Xie, H., Liu, Y., Xia, C., Cun, X., Long, Y., Chen, X., Deng, M., Guo, R., Zhang, Z., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.019 · Cited by 129
Key role of pancreatic stellate cells in pancreatic cancer
Pothula, S. P., Xu, Z., Goldstein, D., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.035 · Cited by 126
DrugTargetSeqR: a genomics- and CRISPR-Cas9–based method to analyze drug targets
Kasap, C., Elemento, O., & Kapoor, T. M. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1551 · Cited by 124
Pusceddu, S., Ghidini, M., Torchio, M., Corti, F., Tomasello, G., Niger, M., Prinzi, N., Nichetti, F., Coinu, A., Bartolomeo, M. D., et al. (2019) · Cancers · doi:10.3390/cancers11040484 · Cited by 122
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells
Saiki, Y., Yoshino, Y., Fujimura, H., Manabe, T., Kudo, Y., Shimada, M., Mano, N., Nakano, T., Lee, Y., Shimizu, S., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.03.122 · Cited by 114
Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance
Leprieur, E. G., Costantini, A., Ding, V. W., & He, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092835 · Cited by 112
Bhutia, Y. D., Hung, S. W., Patel, B., Lovin, D., & Govindarajan, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2736 · Cited by 111
Ohhashi, S., Ohuchida, K., Mizumoto, K., Fujita, H., Egami, T., Yu, J., Toma, H., Sadatomi, S., Nagai, E., & Tanaka, M. (2008) · PubMed · Cited by 111
The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy
Hui, M. N., Cazet, A., Nair, R., Watkins, D. N., O'Toole, S. A., & Swarbrick, A. (2013) · Breast Cancer Research · doi:10.1186/bcr3401 · Cited by 109
Lambies, G., Miceli, M., Martínez-Guillamon, C., Olivera-Salguero, R., Peña, R., Frías, C.-P., Calderón, I., Atanassov, B. S., Dent, S. Y. R., Arribas, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0753 · Cited by 99
Huang, F., Zhuansun, Y., Zhuang, Y., WEI, S.-L., Tang, J., Chen, W., & Zhang, S. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1597 · Cited by 99
Zhang, H., Wu, H., Guan, J., Wang, L., Ren, X., Shi, X., Liang, Z., & Liu, T. (2014) · Oncotarget · doi:10.18632/oncotarget.3099 · Cited by 96
Bergman, A. M., Adema, A. D., Balzarini, J. M., Bruheim, S., Fichtner, I., Noordhuis, P., Fodstad, Ø., Myhren, F., Sandvold, M. L., Hendriks, H. R., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-009-9377-7 · Cited by 96
Tang, S.-W., Thomas, A., Murai, J., Trepel, J. B., Bates, S. E., Rajapakse, V. N., & Pommier, Y. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0443 · Cited by 94
Kohler, I., Bronsert, P., Timme, S., Werner, M., Brabletz, T., Hopt, U. T., Schilling, O., Bausch, D., Keck, T., & Wellner, U. F. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12752 · Cited by 93
Pancreatic cancer: The microenvironment needs attention too!
Apte, M. V., Xu, Z., Pothula, S. P., Goldstein, D., Pirola, R. C., & Wilson, J. S. (2015) · Pancreatology · doi:10.1016/j.pan.2015.02.013 · Cited by 93
Peixoto, R. D., Ho, M., Renouf, D. J., Lim, H. J., Gill, S., Ruan, J. Y., & Cheung, W. Y. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000193 · Cited by 88
Lawlor, R. T., Veronese, N., Nottegar, A., Malleo, G., Smith, L., Demurtas, J., Liang Cheng, C., Wood, L. D., Silvestris, N., Salvia, R., et al. (2019) · Cancers · doi:10.3390/cancers11010113 · Cited by 78
Tostar, U., Toftgård, R., Zaphiropoulos, P. G., & Shimokawa, T. (2010) · Genes & Cancer · doi:10.1177/1947601910385449 · Cited by 74
MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
Xiong, G., Huang, H., Feng, M., Yang, G., Zheng, S., You, L., Zheng, L., Hu, Y., Zhang, T., & Zhao, Y. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0739-x · Cited by 72
Mohelníková-Duchoňová, B., Brynychová, V., Hlaváč, V., Kočík, M., Oliverius, M., Hlavsa, J., Honsová, E., Mazanec, J., Kala, Z., Melichar, B., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2246-2 · Cited by 69
Amponsah, P. S., Fan, P., Bauer, N., Zhao, Z., Gladkich, J., Fellenberg, J., & Herr, I. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.035 · Cited by 63
Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer
Yang, L., Li, F., Gao, F., Xing, L., Qin, P., Liang, X., Zhang, J., Qiao, X.-H., Lin, L., Zhao, Q., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-5321-6 · Cited by 60
Cao, F., LI, J., Sun, H., LIU, S., Cui, Y., & Li, F. (2015) · Oncology Reports · doi:10.3892/or.2015.3789 · Cited by 58
Fan, P., Liu, L., Yin, Y., Zhao, Z., Zhang, Y., Amponsah, P. S., Xiao, X., Bauer, N., Abukiwan, A., Nwaeburu, C. C., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.038 · Cited by 58
The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer
Xiong, G., Feng, M., Yang, G., Zheng, S., Song, X., Cao, Z., You, L., Zheng, L., Hu, Y., Zhang, T., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.020 · Cited by 58
Gu, J., Wang, D., Zhang, J., Zhu, Y., Li, Y., Chen, H., Shi, M., Wang, X., Shen, B., Deng, X., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.016 · Cited by 56
Abdalla, M. Y., Ahmad, I. M., Rachagani, S., Banerjee, K., Thompson, C. M., Maurer, H. C., Olive, K. P., Bailey, K. L., Britigan, B. E., & Kumar, S. (2019) · Translational research · doi:10.1016/j.trsl.2018.12.008 · Cited by 53
Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug
Wu, W., Sigmond, J., Peters, G. J., & Borch, R. F. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070269u · Cited by 52
miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer
REN, Z.-G., Dong, S., Han, P., & Qi, J. (2015) · Oncology Reports · doi:10.3892/or.2015.4534 · Cited by 52
Skrypek, N., Vasseur, R., Vincent, A., Duchêne, B., SEUNINGEN, I. V., & Jonckheere, N. (2015) · Oncotarget · doi:10.18632/oncotarget.3414 · Cited by 48
Wang, C., Zhang, W., Fu, M., Yang, A., Huang, H., & Xie, J. (2014) · Oncology Reports · doi:10.3892/or.2014.3599 · Cited by 45
Blagden, S. P., Rizzuto, I., Suppiah, P., O’Shea, D., Patel, M. D., Spiers, L., Sukumaran, A., Bharwani, N., Rockall, A., Gabra, H., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0244-1 · Cited by 45
Pérez‐Torras, S., Vidal-Pla, A., Cano‐Soldado, P., Huber‐Ruano, I., Mazo, A., & Pastor‐Anglada, M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.173 · Cited by 44
Delitto, D., Black, B. S., Sorenson, H. L., Knowlton, A. E., Thomas, R. M., Sarosi, G. A., Moldawer, L. L., Behrns, K. E., Liu, C., George, T. J., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1820-x · Cited by 44
McAllister, F. M., Pineda, D. M., Jimbo, M., Lal, S., Burkhart, R. A., Moughan, J., Winter, K. A., Abdelmohsen, K., Gorospe, M., Acosta, A. D. J., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28413 · Cited by 43
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine–cardiolipin conjugate
Chen, P., Chien, P.-Y., Khan, A. R., Sheikh, S., Ali, S. M., Ahmad, M. U., & Ahmad, I. N. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000185182.80227.48 · Cited by 42
Ohmine, K., Kawaguchi, K., Ohtsuki, S., Motoi, F., Ohtsuka, H., Kamiie, J., Abe, T., Unno, M., & Terasaki, T. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00282 · Cited by 39
Guo, Z., Wang, F., Yang, D., Yao, L., Yu, X., Fu, D., Li, J., & Jin, C. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s166769 · Cited by 38
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors
Stuurman, F. E., Voest, E. E., Awada, A. H., Witteveen, P. O., Bergeland, T., Hals, P., Rasch, W., Schellens, J. H. M., & Hendlisz, A. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9925-z · Cited by 36
Bachet, J., Hammel, P. R., Desrame, J., Meurisse, A., Chibaudel, B., André, T., Debourdeau, P., Dauba, J., Lecomte, T., Seitz, J., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30046-8 · Cited by 36
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
for the European Study Group for Pancreatic Cancer, Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Campbell, F., Costello, E., Halloran, C. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0004-2 · Cited by 35
Ouyang, Q., Liu, Y., Tan, J., Li, J., Yang, D., Zeng, F., Huang, W., Kong, Y., Liu, Z., Zhou, H., et al. (2019) · PubMed · Cited by 34
Royam, M. M., Ramesh, R., Shanker, R., Sabarimurugan, S., Kumarasamy, C., Nachimuthu, R., Muthukaliannan, G. K., Baxi, S., Gupta, A. K., Krishnan, S., et al. (2019) · Cancers · doi:10.3390/cancers11070900 · Cited by 32
Tian, X., Shivapurkar, N., Wu, Z., Hwang, J. J., Pishvaian, M. J., Weiner, L. M., Ley, L., Zhou, D., Zhi, X., Wellstein, A., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4101 · Cited by 28
Han, Q., Zhou, Y. H., Lyu, Y., Yan, H., & Dai, G. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12655 · Cited by 26
Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance
Du, F., Liu, H., Lu, Y., Zhao, X., & Fan, D. (2017) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2018024855 · Cited by 25
Luan, J., Gao, X., Hu, F., Zhang, Y., & Gou, X. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1616746 · Cited by 25
Guo (2011) · Oncology Reports · doi:10.3892/or.2011.1139 · Cited by 23
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031
Sarr, A., Bré, J., Um, I. H., Chan, T. H., Mullen, P., Harrison, D. J., & Reynolds, P. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-44089-3 · Cited by 18
Shimada, T., Nakanishi, T., Tajima, H., Yamazaki, M., Yokono, R., Takabayashi, M., Shimada, T., Sawamoto, K., Miyamoto, K., Kitagawa, H., et al. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24498 · Cited by 15
Daifuku, R., Koratich, M. S., & Stackhouse, M. A. (2018) · Pharmaceuticals · doi:10.3390/ph11010016 · Cited by 12
Cited by
Liu, R., Wu, J., Guo, H., Yao, W., Li, S., Lu, Y., Jia, Y., Liang, X., Tang, J., & Zhang, H. (2023) · MedComm · doi:10.1002/mco2.292 · Cited by 264
The mechanism of Warburg effect-induced chemoresistance in cancer
Liu, C., Jin, Y., & Fan, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698023 · Cited by 177
Pre-clinical Models of Metastasis in Pancreatic Cancer
Miquel, M., Zhang, S., & Pilarsky, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.748631 · Cited by 53
Self-citationGyoten, M., Luo, Y., Fujiwara-Tani, R., Mori, S., Ogata, R., Kishi, S., & Kuniyasu, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316814 · Cited by 28
Husain, K., Villalobos-Ayala, K., Laverde, V., Vazquez, O. A., Miller, B., Kazim, S., Blanck, G., Hibbs, M. L., Krystal, G., Elhussin, I., et al. (2022) · Cancers · doi:10.3390/cancers14153613 · Cited by 26
Metadata
- Authors
- Zeng, S., Pöttler, M., Lan, B., Grützmann, R., Pilarsky, C., & Yang, H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-09-11
- Volume
- 20
- Issue
- 18
- Pages
- 4504
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2972602909
- Cited by
- 611
- References
- 112
- FWCI
- 22.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.